A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma (ELEVATE HNSCC)
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in patients with head and neck squamous cell carcinoma (HNSCC).
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Head and Neck Squamous Cell Carcinoma
Gender
N/A
Date
September 2021 - July 2025
Study Type
Interventional
Study Phase
Phase 2
Product
Magrolimab, Pembrolizumab, Docetaxel, 5-FU, Cisplatin, Carboplatin, Zimberelimab
Chandler, Arizona, United States, 85224
Duarte, California, United States, 91010
Los Angeles, California, United States, 90095
Palo Alto, California, United States, 94305
Redondo Beach, California, United States, 90277
Santa Rosa, California, United States, 95403
Hollywood, Florida, United States, 33021
Ocala, Florida, United States, 34471
Athens, Georgia, United States, 30607
Indianapolis, Indiana, United States, 46202
Minneapolis, Minnesota, United States, 55407
Saint Louis, Missouri, United States, 63110
East Brunswick, New Jersey, United States, 08816
New York, New York, United States, 10029
Port Jefferson Station, New York, United States, 11776
Fargo, North Dakota, United States, 58122
Oklahoma City, Oklahoma, United States, 73104
Lancaster, Pennsylvania, United States, 17602
Charleston, South Carolina, United States, 29425
Sioux Falls, South Dakota, United States, 57105
Houston, Texas, United States, 77030
Salt Lake City, Utah, United States, 84112
Darlinghurst, New South Wales, Australia, 2010
Macquarie Park, New South Wales, Australia, 2109
Westmead, New South Wales, Australia, 2145
Cairns, Queensland, Australia, 4870
Sippy Downs, Queensland, Australia, 4556
Woolloongabba, Queensland, Australia, 4102
Heidelberg, Victoria, Australia, 3084
Melbourne, Victoria, Australia, 3004
Antwerpen, Belgium, 2020
Brasschaat, Belgium, 2930
Edegem, Belgium, 2650
Leuven, Belgium, 3000
Libramont-Chevigny, Belgium, 6800
Mechelen, Belgium, 2800
Namur, Belgium, 5000
Bordeaux, France, 33000
Dijon, France, 21079
Lyon, France, 69373
Marseille, France, 13005
Nice, France, 6189
Paris, France, 75005
Paris, France, 75013
Pierre-benite, France, 69310
Suresnes, France, 92151
Villejuif, France, 94805
Berlin, Germany, 10177
Bonn, Germany, 53127
GÃttingen, Germany, 37075
Hamburg, Germany, 22087
Leipzig, Germany, 4103
Munich, Germany, 81675
Hong Kong, Hong Kong
Lai Chi Kok, Hong Kong
Bologna, Italy, 40138
Brescia, Italy, 25123
Lucca, Italy, 55100
Milan, Italy, 20133
Modena, Italy, 41124
Reggio Emilia, Italy, 42100
Siena, Italy, 53100
Bydgoszcz, Poland, 85-796
Gliwice, Poland, 44-102
Poznan, Poland, 61-866
Siedlce, Poland, 08-110
Warsaw, Poland, 2781
Braga, Portugal, 4710-243
Faro, Portugal, 8000-366
Lisboa, Portugal, 1998-018
Matosinhos, Portugal, 4464-513
Porto, Portugal, 4050-011
Porto, Portugal, 4200-072
Barcelona, Spain, 08035
Barcelona, Spain, 8003
Barcelona, Spain, 8041
Jaen, Spain, 23007
Madrid, Spain, 28007
Madrid, Spain, 28033
Madrid, Spain, 28046
Malaga, Spain, 29010
Pamplona, Spain, 31008
Sevilla, Spain, 41009
Sevilla, Spain, 41013
Valencia, Spain, 46026
Valencia, Spain
London, United Kingdom, SM2 5PT
Taunton, United Kingdom, TA1 5DA
Share Trial